More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis.
Medical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy umberto.basso@ioveneto.it.
U
U
Basso
Medical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
M
M
Maruzzo
D001859:Bone Neoplasms / Q000188:drug therapy*; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use*
D007211:Indoles; D011758:Pyrroles